G2GBIO

456160 · KOSDAQ · ₩456160 · 지투지바이오

₩39,150▼ ₩6,050 (13.38%)End-of-day · Oct 27, 2026 · End-of-day prices.
Trade
Alert me

Valuation model · Discounted cash flow (DCF)

We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.

Fair value per share

₩5,084

vs the current price (₩39,150)

Enterprise value
₩6B
Equity value
₩85B
WACC
8.1%

Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.

Why the model and the price differ

The model is 87% away from today's price. A gap this size usually means the market expects something the past figures don't show yet, or the model leaves something out. What we can see:

  • No operating margin up to 90% gets the model to today's price at these growth assumptions.

Treat the model as a starting point: change the assumptions to the story you believe, and compare with the multiples check below.

Bear / Base / Bull

Bear
₩5,130
−86.9%
Base
₩5,084
−87.0%
Bull
₩4,979
−87.3%

Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.

Assumptions

Sign in to change the assumptions and see the results update. Sign in

Cycle options

Margin path

Every year uses the cycle-average margin (−20.0%).

Revenue growth

  • -10%

    How much sales grow that year, compared with the year before.

    Default: the last 1 years' revenue growth (-45% a year, annual reports), fading to 3% by year 5.

  • -6.7%

    How much sales grow that year, compared with the year before.

    Default: the last 1 years' revenue growth (-45% a year, annual reports), fading to 3% by year 5.

  • -3.5%

    How much sales grow that year, compared with the year before.

    Default: the last 1 years' revenue growth (-45% a year, annual reports), fading to 3% by year 5.

  • -0.2%

    How much sales grow that year, compared with the year before.

    Default: the last 1 years' revenue growth (-45% a year, annual reports), fading to 3% by year 5.

  • 3%

    How much sales grow that year, compared with the year before.

    Default: the last 1 years' revenue growth (-45% a year, annual reports), fading to 3% by year 5.

Business

  • -20%

    Operating profit as a share of revenue.

    Default: through-the-cycle average of the last 12 months and the last 2 annual reports' operating margins.

  • 27.5%

    Share of operating profit paid as corporate tax.

    Default: Korea's top corporate tax rate (25%) plus 10% local income tax.

  • 294.2%

    The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).

    Default: average of the last 2 annual reports (cash flow statements; equipment and intangibles).

  • 76.2%

    Money spent on factories, equipment, software and other long-term assets (% of revenue).

    Default: average of the last 2 annual reports (cash flow statements; equipment and intangibles).

  • -10%

    Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.

    Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 2 years.

Discount rate

  • 2%

    How fast cash flows keep growing every year after year 5.

    Default: about Korea's long-run inflation plus real growth.

  • 4.11%

    Yield on Korea's 10-year government bond: the return with almost no risk.

    Default: Korea Treasury Bond 10-year yield on 2026-10-28.

  • 0.73

    How much the share moves when the market moves: 1 means just like the market.

    Default: 63 weeks of weekly returns against KOSPI (official index); raw beta 0.6, adjusted toward 1 and kept between 0.6 and 2.0.

  • 5.5%

    The extra return investors want for owning shares instead of bonds.

    Default: a typical premium for Korean shares.

  • 5.61%

    The interest rate the company would pay to borrow.

    Default: the 10-year yield plus a 1.5% credit spread.

Starting point

Revenue (TTM to H1 2026)
₩2.2B
Net debt (borrowings and leases − cash and deposits)
−₩78B
+ Stakes and investments
₩400M
Associates, long-term financial assets and deposits (book value)
Shares
16,629,426
Share price
₩39,150
Market cap
₩651B

TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.

Past years and projection

Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.

FY2024FY2025Year 1Year 2Year 3Year 4Year 5
Revenue₩769M₩423M₩2B₩1.9B₩1.8B₩1.8B₩1.8B
Growth—−45.0%−10.0%−6.7%−3.5%−0.2%3.0%
EBIT−₩11B−₩12B−₩399M−₩372M−₩359M−₩358M−₩369M
EBIT margin−1,399.8%−2,884.2%−20.0%−20.0%−20.0%−20.0%−20.0%
After-tax EBIT−₩7.8B−₩8.8B−₩289M−₩270M−₩260M−₩260M−₩268M
+ Depreciation₩1.8B₩1.5B₩5.9B₩5.5B₩5.3B₩5.3B₩5.4B
− Capital spending₩584M₩324M₩1.5B₩1.4B₩1.4B₩1.4B₩1.4B
− Working capital—₩134B₩22M₩13M₩6.5M₩359,039−₩5.4M
Free cash flow−₩6.6B−₩142B₩4B₩3.8B₩3.6B₩3.6B₩3.8B
Discount factor——0.9250.8550.7910.7320.677
Present value——₩3.7B₩3.2B₩2.9B₩2.7B₩2.5B

Terminal value −₩13B, worth −₩9.1B today: -153% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.

Sensitivity

Fair value per share as two inputs change; the middle is the current case.

WACC ↓ · Terminal growth →1.0%1.5%2.0%2.5%3.0%
7.1%₩5,087₩5,034₩4,970₩4,894₩4,798
7.6%₩5,129₩5,085₩5,034₩4,972₩4,896
8.1%₩5,165₩5,127₩5,084₩5,033₩4,973
8.6%₩5,194₩5,162₩5,125₩5,083₩5,033
9.1%₩5,217₩5,190₩5,159₩5,123₩5,082

Now (TTM)

Market cap
₩651B
Enterprise value
₩572B
P/E
—
P/B
4.7×
P/S
293.9×
EV/EBITDA
—
Dividend yield
0.0%

Over time (at each year end)

2025
Price₩67,000
Market cap₩1.1T
P/E—
P/B19.1×
P/S2,633.5×
EV/EBITDA—
Dividend yield0.0%

Loading data for this company — check back soon

Versus similar companies

CompanyP/EP/BP/SEV/EBITDADividend yield
G2GBIO—4.7×293.9×—0.0%
Samsung Biologics32.1×7.6×14.0×—0.0%
Celltrion27.8×2.4×8.9×—0.0%
Alteogen78.8×28.4×59.9×—0.1%
Yuhan24.8×2.5×2.6×32.5×0.8%
SK biopharmaceuticals14.6×5.7×6.8×—0.0%
HLB—15.4×54.6×—0.0%
Similar companies (median)27.8×6.7×11.5×32.5×0.0%

Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.

Also known as: G2GBIO / 지투지바이오 / 456160 / KRX:456160

Source: KRX statistical information